- Home
- PFL vs CLLS Comparison
PFL vs CLLS Comparison
Compare PFL & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PFL | CLLS |
|---|---|---|
| Founded | 2003 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 395.7M | 394.4M |
| IPO Year | 2003 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PFL | CLLS |
|---|---|---|
| Price | $7.83 | $2.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | ★ 237.9K | 15.9K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 11.53% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.52 | $2.35 |
| 52 Week High | $8.70 | $5.48 |
Technical Indicators
Market Signals| Indicator | PFL | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 60.24 | 52.00 |
| Support Level | $7.62 | $2.65 |
| Resistance Level | $7.90 | $2.99 |
| Average True Range (ATR) | 0.08 | 0.16 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 92.00 | 85.94 |
Price Performance
Historical ComparisonAbout PFL PIMCO Income Strategy Fund Shares of Beneficial Interest
PIMCO Income Strategy Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek high current income, consistent with the preservation of capital. The company seeks to achieve its objectives by investing in a diversified portfolio of floating and fixed-rate debt instruments.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.